STA
DMRA

Summit Trail Advisors’s Damora Therapeutics DMRA Stock Holding History

Summit Trail Advisors’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,000
Closed -$11.9K – 734
2024
Q2 		$11.9K Hold
1,000
– – ﹤0.01% 615
2024
Q1 		$19.5K Buy
+1,000
New +$17.8K ﹤0.01% 607

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Summit Trail Advisors's DMRA Position: Q3 2024 in Review

Summit Trail Advisors sold out of Damora Therapeutics (DMRA) in Q3 2024, closing a stake of 1,000 shares — an estimated $11.9K sold.

Summit Trail Advisors first reported a position in DMRA in Q1 2024 and held it in 2 quarters. The position peaked at $19.5K in Q1 2024. 10 funds tracked by Wall St. Rank hold DMRA as of Q3 2024.

  • Summit Trail Advisors reported no remaining Damora Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 1,000 Damora Therapeutics shares in Q3 2024, an estimated $11.9K.
  • Summit Trail Advisors first reported a position in Damora Therapeutics in Q1 2024 and held it in 2 quarters.
  • Summit Trail Advisors's Damora Therapeutics position peaked at $19.5K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2024.

Based on Summit Trail Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.